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Abstract Group II phospholipase A2 (PLA2) is a mediator of 
inflammation in various disease including glomerulonephritis. We 
recently found that urinary excretion of PLA 2 was increased in 
patients with mesangial proliferative glomerulonephritis and that 
interleukin-I (IL-1) enhanced platelet derived growth factor- 
stimulated mesangial cell proliferation through the action of 
group II PLA2 secreted in response to IL-1 stimuli. Here we 
report signal transducing mechanism through group II PLA2 in 
mesangial cells. Group II PLA2 (1-15 Ulml) rapidly activated 
mitogen-activated protein (MAP) kinase. IL-I~ activated MAP 
kinase in two phases and the slow activation in the late phase, 
proceeding in parallel with increased group II PLA2 secretion 
elicited by IL-1 treatment, was inhibited by the specific antibody 
raised against group II PLA z. This suggests that the late phase 
activation of IL-l-induced MAP kinase was mediated, at least in 
part, by secreted group II PLA2. 
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1. Introduction 
Recently an increasing number of patients have been intro- 
duced into maintenance dialysis due to chronic glomerulone- 
phritis. Thus the mechanism involved in the progression of 
glomerulonephritis must be explored and clarified. Prolifera- 
tion of glomerular mesangial cells is the predominant finding 
of glomerulonephritis at its progressive stage. Recent studies 
have shown that many cytokines, growth factors and vasoac- 
tive substances stimulate the proliferation of mesangial cells [1]. 
Interleukin-1 (IL-1) has been known to act as an autocrine 
factor to promote the progression of some types of glomeru- 
lonephritis in human and in experimental models [2-4]. Me- 
sangial cells express IL-1 receptors and respond to IL-1 stimuli 
to promote cell proliferation, expression of cytokines and cell- 
adhesion molecules, and production of proinflammatory sub- 
stances uch as prostaglandins. We have reported that IL-I 
enhanced the platelet derived growth factor (PDGF)-stimu- 
lated proliferation of mesangial cells through the increased 
secretion of group II phospholipase A 2 (PLA2) from these cells 
[5]. Group II PLA2, believed to be a rate limiting enzyme of 
arachidonic acid cascade, participates in mediating inflamma- 
tory processes in various diseases such as rheumatoid arthritis, 
systemic lupus erythematosus, ulcerative colitis and Crohn's 
disease [6,7]. Concerning renal disease, we found that urinary 
excretion of group II PLA2 was significantly increased in pa- 
tients with mesangial proliferative glomerulonephritis including 
IgA nephropathy, suggesting that group II PLA 2 plays an im- 
portant role in the inflammatory process of glomerulonephritis 
(manuscripts prepared). 
Despite these previous tudies, the signaling pathway of IL-1 
and group II PLA2 in mesangial cells remains to be elucidated. 
Recently Huwiler et al. reported that IL-1 stimulated biphasic 
activation of mitogen-activated protein (MAP) kinase in me- 
sangial cells [8]. MAP kinase, activated quickly in response to 
various extracellular signals, plays a key role in integrating 
diverse signaling pathways [9,10]. We report here that group II 
PLA2 activates MAP kinase rapidly in mesangial cells and 
group II PLA2-induced MAP kinase activation is involved in 
the prolonged activation of MAP kinase by IL-1. These results 
are consistent with the action of group II PLA2 as an autocrine 
mitogenic factor and suggest the involvement of group II PLA2- 
induced MAP kinase activation i  the progression ofmesangial 
proliferative glomerulonephritis. 
2. Materials and methods 
2.1. Materiab 
Recombinant human IL-lfl (5 x 108 U/mg) was obtained from Gen- 
zyme (Cambridge, MA). RPMI 1640 medium was obtained from Nissui 
Pharmaceutical Co. Ltd. (Tokyo, Japan). Bovine serum albumin (BSA; 
fatty acid free), bovine myelin basic protein (MBP) and lysophosphat- 
idic acid were purchased from Sigma. Group II PLA~_ was purified from 
rat spleen [11,12] and group I PLAz was purified from rat pancreas [13] 
according to the method escribed previously. Immunoglobulin against 
group II PLA: was prepared as described previously [14]. This immu- 
noglobulin at the concentration f 570/zg/ml a most completely inhib- 
ited PLA 2 activity in culture media of IL-l-stimulated mesangial cells 
(activity of PLA 2 was inhibited from 1.84 to 0.16 U/mg cell protein). 
Monoclonal mouse anti-MAP kinase antibody was obtained from 
Zymed. 
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2.2. Mesangial cell culture and stimulation 
Rat mesangial cells were isolated and cultured as described previ- 
ously [15,16]. Mesangial cells in passage (~12 were grown to 80% 
confluent state and then cultured in RPMI 1640 containing 0.5% fetal 
calf serum for 48 h. Quiescent cells in 100 mm dishes were incubated 
in RPMI 1640 containing 1mg/ml BSA and 20 mM HEPES (pH 7.4) 
for 1 h before stimulation. Then various timulants were added in the 
medium and cells were incubated for indicated period. 
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2.3. Preparation of eytosol fraction 
After the treatment of cells with stimulants, cytosol fractions were 
prepared as described previously [17]. Briefly, cells were scraped off 
with ice-cold freshly prepared homogenizing buffer (20 mM Tris-HC1, 
pH 7.4, containing 2 mM EGTA, 10 mM fl-glycerophosphate, 1 mM 
sodium orthovanadate, 1 mM dithiothreitol, 1/.tM p-amidinophenyl- 
methanesulfonyl fluoride and 100 kallikrein inactivator U/ml aprotinin) 
and homogenized bybrief sonication. The homogenate was ultracentri- 
fuged and the supernatant was collected as the cytosol fraction. 
2.4. Measurements of PLA e activity 
PLA z activity in culture medium was assayed after the treatment with 
IL-lfl as described previously using 1-palmitoyl-2-oleoyl-sn-glycerol-3- 
phosphoglycerol as a substrate [7,12]. One unit of PLA2 activity was 
represented as 1 nmol of oleic acid released from 1-palmitoyl-2-oleoyl- 
sn-glycerol-3-phosphoglycerol per minute. 
2.5. Immunoblotting and assay of MAP kinase activity 
Immunoblotting of MAP kinase was performed as described previ- 
ously [17]. To detect signals of immunoblotting, biotin-labeled goat 
anti-mouse IgG and avidin/biotin system were used (Vector Labs Inc., 
Burlingame, CA). Activity of MAP kinase was measured by the in-gel 
kinase assay as described previously, using bovine MBP as the substrate 
[18,19]. In brief, each aliquots (40/,tg protein) of cytosol fraction of 
mesangial cells were applied on SDS-10% polyacrylamide g l contain- 
ing 0.5 mg/ml MBP. After electrophoresis, the gels were immersed in 
6 M guanidine hydrochloride containing 50 mM Tris-HCl and 5 mM 
2-mercaptoethanol, and then transferred to renaturing buffer (50 mM 
Tris-HC1 containing 0.08% polyoxyethylene sorbitan monolaurate 
(Tween 20) and 5 mM 2-mercaptoethanol). Thegels were incubated 
with [y-32p]ATP after renaturation, dried on filter paper and subjected 
to autoradiography. The radioactivity was measured by a bioimaging 
analyzer and the amount of incorporated phosphate was calculated 
using specific activity of [y-32p]ATP. (BAS2000; Fuji Photo Film Co. 
Ltd., Tokyo, Japan). 
3. Results 
3.1. MAP kinase activation by IL-1 
Quiescent mesangial cells were incubated with 200 U/ml IL- 
lfl and then MAP kinase activity of the cell lysate was meas- 
ured. In-gel kinase assay showed two bands at 44- and 42-kDa 
positions (Fig. 1A). Immunoblotting using anti-MAP kinase 
monoclonal antibody confirmed the bands corresponded to 
MAP kinases (Fig. 1C). We confirmed IL-l- induced biphasic 
activation of MAP kinase as reported previously [8]. The activ- 
ity of 44-kDa MAP kinase (p44 MAP kinase) reached its max- 
imum 20 min after the stimulation and then returned to basal 
level in 1 h, followed by a steady increase lasting over 24 h (Fig. 
I B). Similar results were obtained for the p42 MAP kinase. 
Huwiler et al. observed that the late phase-increase in MAP 
kinase activity was accompanied by de novo synthesis of MAP 
kinase protein. However, little increase in MAP kinase proteins 
was detectable during the incubation in our experiments, ug- 
gesting that MAP kinase activation ismainly caused by enhanc- 
ing the kinase activity but not by increasing the kinase protein. 
During this time period, cell number was not changed. 
3.2. MAP kinase activation by group H PLA2 
We therefore investigated the mechanism involved in the 
1L-l-induced late phase activation of MAP kinase. It is re- 
ported that IL-lfl stimulates mesangial cells to secrete group II 
PLA2 [20] and we have already obtained evidence that the 
secreted group II PLA2 mediates the IL-lfl-induced prolifera- 
tion ofmesangial cells [5]. Fig. 1D shows the activity of group 
II PLA2 appeared in the culture medium. Since the time course 
of the IL-l- induced late phase activation resembled to that of 
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Fig. 1. Time courses of MAP kinase activation and group II PLA 2 
secretion by IL-lfl. Rat mesangial cells in passages 6-12 were stimu- 
lated by 200 U/ml IL-lfl. Cytosol fractions of mesangial cells exposed 
to 200 U/ml IL-lfl for indicated times were processed as described in 
section 2. (A) Autoradiographic detection of 32p-labeled MBP by in-gel 
kinase assay. (B) IL-lfl induced changes in p44 MAP kinase activity 
measured by bioimaging analyzer. • -- MAP kinase activity of me- 
sangial cells stimulated by 200 U/ml IL-lfl; © = the basal activity of 
MAP kinase measured under the same condition without IL-lfl. (C) 
Immunoblotting of the cell lysate with anti-MAP kinase antibody. (D) 
The secretion of PLA2 from mesangial cells. The PLA 2 activities in the 
culture media from 200 U/ml IL-lfl-stimulated (•) and non-stimulated 
(o) mesangial cells were measured as described in section 2. 
the secretion of PLA2, we studied the effects of exogenous 
group II PLA 2 on MAP kinase activity to elucidate the signal 
transducing mechanism of group II PLA 2 in mesangial cell 
proliferation. Addition of 14 U/ml group II PLA 2 rapidly acti- 
vated 44-kDa and 42-kDa MAP kinase (p44 and p42 MAP 
kinase) (Fig. 2A,B). As p44 MAP kinase and p42 MAP kinase 
were activated similarly, the figures show the activity of p44 
MAP kinase as the representative. The activity reached its 
maximum in l0 min and increased almost linearly up to 10 U/ml 
to get to the plateau (Fig. 2C,D). These data suggest hat the 
IL- 1-induced late phase activation of MAP kinase may be me- 
diated by secreted group II PLA 2. On the contrary, group I 
PLA2 (10 U/ml), the other isoform of secretory PLA> activated 
MAP kinase weakly by at most 25% of the increments in re- 
sponse to group II PLA2 stimulation at the same concentration 
(Fig. 3). 
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3.3. Inhibition of MAP kinase activation by anti-group H PLA 2 
antibody 
Next we studied the effect of anti-group II PLA2 immunog- 
lobulin on IL-l-induced MAP kinase activation to examine 
whether group II PLA2 was involved in the IL-lfl-evoked sig- 
naling pathway. Anti-group II PLA 2 immunoglobulin used in 
this study blunted the stimulatory effect of IL-1 on mesangial 
cell proliferation (data not shown). As shown in Fig. 4, the 
activation of MAP kinases was inhibited 10 h after IL-lfl- 
stimulation when cells were treated with anti-group II PLA2 
immunoglobulin, lmmunoglobulin prepared from non-immu- 
nized rabbit did not affect MAP kinase activity (data not 
shown). 
3.4. Effects of lysophosphatidic a id 
Lysophospholipids are putative signaling molecules pro- 
duced by PLAz-catalyzed reaction. We have already demon- 
strated that lysophosphatidic a id (LPA) was the most potent 
mitogen among several lysophospholipids for mesangial cells. 
LPA has been reported to activate MAP kinase in some types 
of cell [21-23]. We observed here that LPA activated MAP 
kinase also in mesangial cells. The activity reached maximum 
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Fig. 2. MAP kinase activation by group II PLA 2. Experimental condi- 
tions were the same as in Fig. 1 except that rat mesangial cells were 
incubated with group II PLA2 in place of IL-lfl. (A and B) Time course 
of MAP kinase activation induced by the addition of 14 U/ml group 
II PLA 2. (C and D) Dose-dependence of MAP kinase activation by 
group II PLA 2. 
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Fig. 3. Effects of group I PLA 2 on MAP kinase activation. Rat me- 
sangial cells were incubated in the culture media containing no ligand 
(control), 10 U/ml group I PLA2 (I) or 10 U/ml group II PLAz (II) for 
10 min. The activity of p44 MAP kinase was measured as described 
under legend of Fig. 1. 
in l0 min and the maximal activity was eight times higher than 
the basal activity (activity of p44 MAP kinase: 1.37 pmol and 
0.17 pmol). 
4. Discussion 
The present study demonstrates the activation of MAP ki- 
nase by exogenous group II PLA2 in cultured mesangial cells. 
IL-lfl activates MAP kinase in two phases in agreement with 
previous results: a rapid and prominent activation, followed by 
a continuous stimulation persisting for more than 24 h. The 
time course of the late phase activation was paralleled to that 
of the secretion of group II PLAz from mesangial cells stimu- 
lated by IL-lfl and the late phase activation was notably inhib- 
ited by the specific antibody against group II PLA2. Taken 
together with the observation that exogenous group II PLA2 
rapidly activated MAP kinase, these data suggest that the pro- 
longed MAP kinase-activation might be mediated through the 
secretion of group II PLA 2 from IL-l-stimulated mesangial 
cells. In addition, the deprivation of IL-1 from culture medium 
6 h after the stimulation did not attenuate he late phase MAP 
kinase-activation (data not shown), suggesting that the IL-1 
existing in media did not affect the prolonged MAP kinase- 
activation. Concerning the rapid and prominent activation of 
MAP kinase by IL-1, it may be possible that the rapid activa- 
tion contributes a  the initial signaling event o the secretion of 
group II PLA2, though the function is still to be elucidated. 
Recent studies demonstrated that the activation of MAP 
kinases was involved in a variety of cell function. Some growth 
factors besides IL-1 was also shown to activate MAP kinase 
biphasically, and a steady increase in MAP kinase activity in 
the late phase is supposed to be important for DNA synthesis 
and cell cycle progression [24]. Considering our previous data 
that group II PLA 2 amplified PDGF-stimulated proliferation 
of mesangial cells, the late phase activation of MAP kinase by 
IL-1 through the secretion of group II PLA2 may also contrib- 
ute to the cell cycle progression. 
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Fig. 4. Inhibition of MAP kinase activation by anti-group II PLA2 
antibody. Rat mesangial cells were stimulated by IL-lfl as in Fig. 1 with 
or without anti-group II PLA2 immunoglobulin (140/lg/ml) in culture 
media. Activity of MAP kinase was measured 10 h after stimulation 
using in-gel kinase assay. (A) Autoradiography. (B)MAP kinase activ- 
ity expressed as percentage of p44 MAP kinase activity with IL-lfl 
minus immunoglobulin. The basal activity (control) was measured 
without IL-1 and immunoglobulin. 
Concerning the signal transduction pathway through which 
group II PLA2 activated MAP kinase, the following two possi- 
ble mechanism can be considered. First, group II PLA 2 may 
activate MAP kinase through yielding metabolites of PLAR- 
catalyzed reaction. Lysophosphatidic a id (LPA) is one of these 
metabolites. We previously observed that LPA as well as group 
II PLA2 enhanced the PDGF-stimulated proliferation of me- 
sangial cells. Very recently, Fourcade t al. reported that group 
II PLA2 generates LPA in membrane microvesicles shed from 
activated cells [25]. LPA has been reported to activate MAP 
kinase in some types of cells [21-23]. We confirmed that LPA 
stimulated the activation of MAP kinase also in mesangial cells. 
It is likely that LPA generated by the action of group II PLA2 
on mesangial cell membrane induced the action of MAP kinase. 
Another metabolite of PLA2-catalyzed reaction, fatty acids, 
have been also reported to play some physiological role in cell 
function. Among them, arachidonic acid is a well-known pre- 
cursor of potent pro-inflammatory substances such as prosta- 
glandins and leukotriens. However, arachidonic acid had no 
significant effect on mesangial cell proliferation (manuscripts 
submitted). Thus we turned our attention to LPA as a signaling 
molecule. Second, group II PLA2 may activate the MAP kinase 
via its specific receptor. Recently, the receptors for secretory 
PEA 2 has been cloned [26,27], and they were involved in various 
physiological responses such as DNA synthesis [28] and eicosa- 
noid production [29]. Lambeau et al. cloned and characterized 
the receptor for snake venom PLA 2 from rabbit skeletal muscle. 
The receptor had binding capacity to mammalian secretory 
PLA 2 with high affinity, and the affinity for group II PLA 2 was 
about en times higher than that for group I PLA 2 [27] This is 
consistent with the fact that group I PLA2 did not activate 
MAP kinase so strongly as group II PLA 2 using the equivalent 
units of activity. However, more recently Ancian et al. also 
cloned the human receptor for PLA 2 and showed that the 
expressed receptor had little binding affinity toward both group 
I and group I1 PLA2 [30]. The role of the receptor for PLA2 in 
the MAP kinase activation i duced by PLA2 still remains to be 
elucidated. 
In conclusion, we first demonstrated that group II PLA2 
activated MAP kinase in rat mesangial cells and that the IL-1- 
induced late phase activation of MAP kinase was mediated, at 
least in part, by secreted group II PLA2, suggesting that group 
II PLA2-induced MAP kinase activation is involved in the 
progression of mesangial proliferative glomerulonephritis. 
These results will throw light on the mechanism of the progres- 
sion of mesangial proliferative glomerulonephritis. 
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